GIPIO
Gastro-intestinal Peptides in Obesity
| Coordinatore | UNIVERSITAET LEIPZIG
Organization address
address: RITTERSTRASSE 26 contact info |
| Nazionalità Coordinatore | Germany [DE] |
| Sito del progetto | http://www.gipio.eu |
| Totale costo | 5˙375˙872 € |
| EC contributo | 3˙857˙407 € |
| Programma | FP7-HEALTH
Specific Programme "Cooperation": Health |
| Code Call | FP7-HEALTH-2007-B |
| Funding Scheme | CP-TP |
| Anno di inizio | 2008 |
| Periodo (anno-mese-giorno) | 2008-10-01 - 2012-09-30 |
Partecipanti
| # | ||||
|---|---|---|---|---|
| 1 |
UNIVERSITAET LEIPZIG
Organization address
address: RITTERSTRASSE 26 contact info |
DE (LEIPZIG) | coordinator | 1˙230˙393.23 |
| 2 |
7TM PHARMA AS
Organization address
address: FREMTIDSVEJ 3 contact info |
DK (HOERSHOLM) | participant | 794˙815.77 |
| 3 |
KING'S COLLEGE LONDON
Organization address
address: Strand contact info |
UK (LONDON) | participant | 432˙840.00 |
| 4 | KOBENHAVNS UNIVERSITET | DK | participant | 405˙952.00 |
| 5 |
HELMHOLTZ-ZENTRUM DRESDEN-ROSSENDORF EV
Organization address
address: BAUTZNER LANDSTRASSE 400 contact info |
DE (DRESDEN) | participant | 377˙881.00 |
| 6 |
ZEALAND PHARMACEUTICALS AS
Organization address
address: SMEDELAND 36 contact info |
DK (GLOSTRUP) | participant | 330˙000.00 |
| 7 |
POLYPEPTIDE LABORATORIES AS
Organization address
address: HERREDSVEJEN 2 contact info |
DK (HILLEROED) | participant | 285˙525.00 |
Mappa
Word cloud
Esplora la "nuvola delle parole (Word Cloud) per avere un'idea di massima del progetto.
Obiettivo del progetto (Objective)
'Obesity is the fasted growing health problem in the Western World. In the United States, obesity as cause of preventable mortality (365,000 deaths in the year 2000) will soon overtake tobacco (435,000 deaths) and already has overtaken alcohol consumption (85,000 deaths), infectious diseases (75,000) and motor vehicle crashes (43,000). More important, it is also a problem in children and adolescent, and accordingly, one of the major future health problems. We hypothesize that the reduction of hormones/signals, released or blocked after food intake as nutrition signal, significantly contributes to the feed-back in food intake, and subsequently to the onset in obesity. Accordingly, the focus of this project is the understanding of the contribution of gastro-intestinal peptides to the onset of obesity. It is aimed to identify the most relevant hormones or combinations of hormones, and subsequently to develop anti-obesity drugs that are based on endogenous hormone agonists or antagonists. The project will include the following aspects and competences: Production of endogenous hormones by synthetic approaches according to the guidelines of GMP and investigation in human volunteers by fMRT. Most promising candidates will be studied in more detail. This will include ghrelin, orexin, GLP, PP and PYY. Experiments will occur on the molecular, cellular and animal level. Original and optimised hormones will be modified with DOTA and used for labelling, and subsequent analysis in PET studies to allow the follow up of distribution and stability. In a medicinal chemistry concept, non peptidic drugs and peptide mimetics will be further explored for PYY and PP first as well as for ghrelin, orexin and GLP.'
Introduzione (Teaser)
Current approaches to the management of obesity are failing, resulting in an ever-increasing number of cases in many parts of the world. An EU-funded study decided to dissect the hormone-based mechanisms that are implicated in obesity with the ultimate aim of designing effective therapeutic interventions.